Appili Therapeutics Receives Funding from the Government of Canada to Support Development of New Antibiotic To Treat Gram-Negative Infections

April 11, 2017 – HALIFAX, Nova Scotia –– Appili Therapeutics Inc. (“Appili”), an anti-infective drug development company, announced today that it will be receiving an additional $400,000 from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP), bringing IRAP support for this project to a total of up to $759,000. This funding supports the development of ATI-1503, an antibiotic targeting drug-resistant Gram-negative bacteria, superbugs that cause potentially deadly infections.

Details

Appili Therapeutics Awarded $2.8M From ACOA to Fund Clinical Trials

February 17, 2017 – HALIFAX, Nova Scotia –– Appili Therapeutics Inc.(“Appili”), an anti-infective drug development company, announced today that it will be receiving $2,803,148 from the Atlantic Canada Opportunities Agency (ACOA), under the Atlantic Innovation Fund (AIF). This funding will enable Appili to take its first drug, ATI-1501 – a taste-masked, oral antibiotic that treats anaerobic infections like Clostridium difficile – through clinical trials to be ready for market approval.

Details

Appili Therapeutics Raises $2.2M in Equity Capital to Develop Its Anti-Infective Pipeline

December 21, 2016 – HALIFAX, Nova Scotia –– Appili Therapeutics Inc. (“Appili”), an anti-infective drug development company, announced today it raised $2,151,000 in its over-subscribed private placement financing. Participants in this capital raise included current Appili investors such as Innovacorp, as well as new individual and institutional investors. Proceeds from the financing will be used…

Details

Appili Raises $3.2M in Seed Round To Develop Novel Antibiotics

May 25, 2016 – HALIFAX, Nova Scotia –– Appili Therapeutics Inc., an anti-infective pharmaceutical development company, announced today it has raised $3,271,000 to advance the research and development of its anti-infective drug candidates and open a medicinal chemistry lab in Halifax.   “Completing this seed round of investment provides us with a solid base from…

Details

Appili Receives Orphan Drug Designation from FDA for ATI-1501: Treating C. difficile in Children

HALIFAX, Nova Scotia – April 12, 2016 – Appili Therapeutics Inc., an anti-infective pharmaceutical development company, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for ATI-1501, a taste-masked reformulation of metronidazole with the potential to effectively treat Clostridium difficile infection (CDI) in children. CDI is one of the…

Details